Details for New Drug Application (NDA): 022377
✉ Email this page to a colleague
NDA 022377 describes ALSUMA, which is a drug marketed by Meridian Medcl and is included in one NDA. There is one patent protecting this drug. Additional details are available on the ALSUMA profile page.
The generic ingredient in ALSUMA is sumatriptan succinate. There are twenty-four drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the sumatriptan succinate profile page.
The generic ingredient in ALSUMA is sumatriptan succinate. There are twenty-four drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the sumatriptan succinate profile page.
Summary for 022377
| Tradename: | ALSUMA |
| Applicant: | Meridian Medcl |
| Ingredient: | sumatriptan succinate |
| Patents: | 1 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;SUBCUTANEOUS | Strength | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | ||||
| Approval Date: | Jun 29, 2010 | TE: | RLD: | No | |||||
| Patent: | 7,811,254 | Patent Expiration: | Aug 26, 2027 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patented Use: | ACUTE TREATMENT OF MIGRAINE ATTACKS, WITH OR WITHOUT AURA, AND THE TREATMENT OF CLUSTER HEADACHE EPISODES | ||||||||
Complete Access Available with Subscription
